)
Vericel (VCEL) investor relations material
Vericel 2026 Stephens Annual Investment Conference | NASH2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 performance
Q3 2026 revenue topped $85M, up 26% YoY and above guidance; MACI revenue exceeded $67M, up 21% YoY.
Burn care revenue reached a quarterly record, with both products at their highest quarterly revenues; full-year burn care growth was in the ~50% range.
Net income tripled YoY; adjusted EBITDA rose nearly 50% to almost $25M, with strong operating and free cash flow.
MACI commercial momentum
2026 growth drivers include a sales force expanded 30% from Jan. 1, commercial excellence initiatives, and MACI Arthro momentum; initiatives target deeper surgeon penetration and the midterm $500M revenue goal.
Surgeon segmentation uses qualifying-procedure data to focus reps on high-potential practices; standardized playbooks address biopsy volume, implant conversion, administrative barriers, and clinical education.
Biopsy growth increasingly reflects both more surgeons biopsying and more biopsies per surgeon; aggregate conversion is ~1/3 over 18 months to two years, while experienced, high-volume users tend to reach ~50%.
New territories led biopsy growth through Q3 2026; management expects biopsies to convert over subsequent quarters, with new-rep cohorts showing stronger growth in years two and three and no observed pull-forward.
MACI Arthro-trained surgeons include new MACI users; Arthro-only surgeons are starting biopsies and implants, with adoption also creating a halo for MACI open procedures.
UK expansion
UK launch is targeted for H2 2027; the marketing application was submitted in Q2 2026, and the MHRA inspected the new facility in Q3, with GMP certification expected before year-end 2026.
NICE accepted MACI for a single technology appraisal; reimbursement and regulatory tracks are expected to converge in early H2 2027, supporting a 2027 launch target.
NHS treatment is concentrated in about a dozen joint-preservation centers, with a modest training requirement; UK revenue is viewed primarily as a 2028 driver given biopsy-to-implant timing.
- Record Q3 revenue and profit growth lifted FY revenue guidance to $344M–$346M.VCEL
Q3 2026 - MACI and Burn Care drive strong growth, margin expansion, and cash flow, fueling innovation and returns.VCEL
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 revenue up 22%, net income $2.2M, and $200M share repurchase program authorized.VCEL
Q2 2026 - Record revenue, strong pricing, and expanding market opportunities drive robust growth.VCEL
Truist Securities MedTech Conference 2026 - Board nominees elected, compensation and auditor ratified, no shareholder questions submitted.VCEL
AGM 2026 - Q1 revenue up 30% to $68.4M, guidance raised, and profitability improved on strong MACI/Burn Care.VCEL
Q1 2026 - Record revenue, strong growth, and robust governance set the stage for sustained expansion.VCEL
Proxy filing - Record Q4 revenue and profit growth, with strong MACI performance and robust 2026 outlook.VCEL
Q4 2025 - Record 2024 revenue and profitability, with strong 2025 growth and margin expansion expected.VCEL
Q4 2024
)
)
)
)
)
)
)
)